🔎 Trials Near Me

መነሻ › ማይሎዲስፕላስቲክ ሲንድሮሞች › Texas › Houston

በHouston፣ TX ለማይሎዲስፕላስቲክ ሲንድሮሞች የሚደረጉ ክሊኒካዊ ጥናቶች

ለማይሎዲስፕላስቲክ ሲንድሮሞች የሚደረጉ 43 ጥናቶች በHouston እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT05564390

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • University of Texas MD Anderson Cancer Center, Houston
እድሜ ከ12 እስከ 78 · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT03802695

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06548230

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT03661307

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT05320198

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • M D Anderson Cancer Center, Houston
እድሜ 1 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT03630991

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • The University of Texas-MD Anderson Cancer Center - Leukemia Center, Houston
  • LUMI Research, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT07422480

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT03683433

A Study of BGB-11417 in Participants With Myeloid Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Md Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT04771130

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

ተሳታዮችን በመፈለግ ላይደረጃ 2ጤናማ ተሳታዮች ይቀበላሉ
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06566742

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06616636

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT05010122

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • MD Anderson Cancer Centre, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06465953

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04493164

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ኦገስ 2026 · NCT06499285

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ኦገስ 2026 · NCT04419649

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

ተሳታዮችን በመፈለግ ላይደረጃ 2/3ጤናማ ተሳታዮች ይቀበላሉ
  • M D Anderson Cancer Center, Houston
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ11 ኦገስ 2026 · NCT04708054

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ኦገስ 2026 · NCT05308264

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ ከ12 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ7 ኦገስ 2026 · NCT05092451

Personalized NK Cell Therapy in CBT

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ ከ15 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ30 ጁላይ 2026 · NCT02727803

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Research Site, Houston
እድሜ 16 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ጁላይ 2026 · NCT07155226

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University of Texas MD Anderson Cancer Center, Houston
እድሜ 60 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጁላይ 2026 · NCT01515527

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ጁን 2026 · NCT01624805

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁን 2026 · NCT03113643

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ጁን 2026 · NCT02074839

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ጁን 2026 · NCT05365035

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • GSK Investigational Site, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ጁን 2026 · NCT06847867

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሜይ 2026 · NCT04953910

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሜይ 2026 · NCT04953897

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT04239157

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT02115295

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኤፕሪ 2026 · NCT04256317

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ኤፕሪ 2026 · NCT05732103

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ማርች 2026 · NCT07107126

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MDACC, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ማርች 2026 · NCT04988555

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጃንዩ 2026 · NCT05143996

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

ተሳታዮችን በመፈለግ ላይደረጃ 1ጤናማ ተሳታዮች ይቀበላሉ
  • M.D. Anderson Cancer Center, Department of Leukemia, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ኖቬም 2025 · NCT05986240

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Massive Bio SYNERGY-AI site, Houston
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas M.D. Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2025 · NCT06501196

Study of REM-422 in Patients With AML or Higher Risk MDS

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ኤፕሪ 2025 · NCT06297941

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ማርች 2024 · NCT04243785

በሌሎች ከተሞች ለማይሎዲስፕላስቲክ ሲንድሮሞች የሚደረጉ ጥናቶች

በHouston ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።